<DOC>
	<DOCNO>NCT01060098</DOCNO>
	<brief_summary>Inflammatory arthritis particularly rheumatoid arthritis , psoriatic arthritis ankylose spondylitis potentially disabling condition cause joint pain , swell deformity treatment aim preventing complication . Although treatment improved advent antiTNFalpha therapy , 30 % patient fail respond treatment others , treatment associate significant side effect . The precise mechanism remain unclear . In addition , sensitive method available monitor predict disease response treatment aside test inflammatory marker blood . Understanding mechanism action govern response antiTNF therapy allow development specific therapy inflammatory arthritis . Work animal model rheumatoid arthritis characterise novel cell type , Th17 cell , important inflammatory cascade affect particular way antiTNF therapy may underpin mechanism action side effect . We aim translate finding patient rheumatoid arthritis condition treat anti-TNF therapy , psoriatic arthritis ankylose spondylitis . Patients rheumatology clinic within NHS trust recruit . We correlate disease activity assess clinical parameter , ultrasonography questionnaire biomarkers blood target tissue , synovium skin .</brief_summary>
	<brief_title>T Cells TNF : The Impact TNF Blockade</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>General Only antiTNF na√Øve patient include study Patients 18 80 year age Patients due start treatment antiTNF block agent etanercept adalimumab Patients rheumatoid arthritis Only patient meet 1987 American College Rheumatology ( ACR ) revise classification criterion rheumatoid arthritis include Patients active rheumatoid arthritis , define initial DAS28 score &gt; 5.1 Patients least 1 joint suitable synovial biopsy Patients concurrent DMARDs stable dose DMARD least 1 month prior study entry Patients concurrent dose glucocorticoid ( 10mg daily ) stable dose least 4 week prior study entry Patients psoriatic arthritis Patients secure diagnosis psoriatic arthritis determine rheumatologist Patients psoriatic arthritis include study evidence concurrent psoriatic skin lesion time study entry Patients least one joint suitable synovial biopsy Patients concurrent DMARDs stable dose DMARD least 1 month prior study entry Patients Ankylosing spondylitis Patient fulfil Modified New York Criteria diagnosis ankylose spondylitis Patients concurrent NSAIDs Patients concurrent DMARDs stable dose DMARD least 1 month prior study entry Patients previously treat antiTNF therapy whatever reason Patients rheumatoid arthritis , psoriatic arthritis ankylose spondylitis fulfil diagnostic criterion condition Patient receive intraarticular injection steroid receive intramuscular injection depot steroid treat disease flare precede 4 week prior commence antiTNF therapy . Patients intercurrent , active infection type , exclude common cold</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>